Aridis Pharmaceuticals In...
0.00
-0.00 (-100.00%)
At close: Jan 14, 2025, 8:04 PM
undefined%
Bid n/a
Market Cap 4.46K
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.16
PE Ratio (ttm) 0
Forward PE n/a
Analyst Buy
Ask n/a
Volume 600
Avg. Volume (20D) 17,468
Open 0.00
Previous Close 0.00
Day's Range 0.00 - 0.00
52-Week Range 0.00 - 0.09
Beta undefined

About ARDS

Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the discovery and development of targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that is in Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin. The company is also developing AR-32...

Industry Biotechnology
Sector Healthcare
IPO Date Aug 14, 2018
Employees 37
Stock Exchange NASDAQ
Ticker Symbol ARDS

Analyst Forecast

According to 1 analyst ratings, the average rating for ARDS stock is "Buy." The 12-month stock price forecast is $2, which is an increase of 1999900.00% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
No News article available yet